



# State of New Hampshire

DEPARTMENT OF HEALTH AND HUMAN SERVICES

129 PLEASANT STREET, CONCORD, NH 03301-3857  
603-271-9200 FAX: 603-271-4912 TDD ACCESS: RELAY NH 1-800-735-2964

2B  
mac

JEFFREY A. MEYERS  
COMMISSIONER

March 2, 2016

Her Excellency, Governor Margaret Wood Hassan  
and the Honorable Council  
State House  
Concord, New Hampshire 03301

## REQUESTED ACTION

Authorize the Department of Health and Human Services to accept 171 Naloxone Kits from Adapt Pharma, Limited, 100 Matsonford Road, Building 4, Suite 201, Radnor, Pennsylvania, valued in the amount of \$12,825, for Statewide distribution to New Hampshire high schools that wish to participate in the program at no cost to taxpayers effective upon Governor and Executive Council approval, through February 28, 2017. This is 100% Other (Private Grant) Funds.

## EXPLANATION

The purpose of this request is to accept 171 Naloxone Kits from the vendor that will be available for distribution to all New Hampshire high schools wishing to participate in the program including public, private, preparatory, parochial and charter high schools.

On November 18, 2015, the Food and Drug Administration approved a new compact, self-contained intranasal spray device for the reversal of an opioid overdose, which was developed by the vendor. The vendor contacted the Department of Health and Human Services to make the Naloxone Distribution team aware of the new product. In January of 2016, the vendor announced that one free Naloxone Kit would be made available to every high school in the United States and, subsequently, contacted the Department of Health and Human Services and the Department of Education to follow up on the Nationwide offer.

Under the conditions of the offer, each high school wishing to participate in the program will receive:

- 2 dispensers of 4 milligrams of naloxone hydrochloride.
- 1 blister pack container for the 2 dispensers.
- 2 instruction sheets for the use of the intranasal spray device.

High schools in New Hampshire will have to choose to participate in the no cost Naloxone distribution. There are 171 high schools in New Hampshire, including public, private, parochial, preparatory, and charter schools. There is no cost to New Hampshire or to any high school for participation in the program. The program is open to high schools only.

Each kit listed above is sold at \$75 per kit for a total program value of \$12,825. The Department of Health and Human Services will collaborate with the Department of Education to ensure each high school is aware of the availability of the kits. The news release regarding the vendor's offer is attached for reference.

Her Excellency, Governor Margaret Wood Hassan  
and the Honorable Council  
March 2, 2016  
Page 2 of 2

The Department of Education has administrative responsibility for the program, including communication and coordination of deliveries to New Hampshire high schools. The Department of Health and Human services has logistical responsibility for the program, including accepting the kits from the vendor and distributing the kits to participating high schools.


Should the Governor and Executive Council determine not to approve this request, New Hampshire high schools may not have access to a Kit that could quickly reverse an opioid overdose and save a life, if and when an opioid overdose occurs in a high school. Opioid overdoses in high schools would negatively impact New Hampshire citizens on many levels, including students indirectly impacted by witnessing such deaths at their high school.

Geographic area served: Statewide.

Source of Funds: 100% Private.


If private funds become no longer available, general funds will not be requested to support the program expenditures.

Respectfully submitted,



Virginia M. Barry, Ph.D.  
Commissioner  
Department of Education

Respectfully submitted,



Jeffrey A. Meyers  
Commissioner  
Department of Health & Human Services

January 25, 2016 (<http://www.adaptpharma.com/press-releases/>)

## **ADAPT PHARMA TO OFFER ALL U.S. HIGH SCHOOLS A FREE NARCAN NASAL SPRAY AND FUND SCHOOL-BASED OPIOID OVERDOSE EDUCATION**

Dublin, Ireland – January 25, 2016 – Adapt Pharma, Limited ("Adapt Pharma") today announced two national programs at the Clinton Health Matters Initiative Activation Summit to assist in efforts to address the growing risk of opioid overdose among American high-school students. First, Adapt Pharma will offer a free carton of NARCAN® (naloxone hydrochloride) Nasal Spray to all high schools in the United States through the state departments of education. This program will collaborate with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, as part of its work to scale naloxone access efforts nationally.

In addition, Adapt Pharma has provided a grant to the National Association of School Nurses (NASN) to support their educational efforts concerning opioid overdose education materials. To learn more click [here](#) or call 844-4-NARCAN.

NARCAN Nasal Spray is the only FDA approved, ready-to-use, needle-free nasal spray version of naloxone hydrochloride, indicated for the emergency treatment of opioid overdose. It is not a substitute for emergency medical care. See below for indication and important safety information. For multimedia content, please visit <http://inr.synapticdigital.com/adaptpharma/NARCAN/>.

"We understand the crucial role schools can play to change the course of the opioid overdose epidemic by working with students and families. We also want every high school in the country to be prepared for an opioid emergency by having access to a carton of NARCAN Nasal Spray at no cost," said Seamus Mulligan, Chairman and CEO of Adapt Pharma. "We look forward to working with our partners to implement these initiatives which build on the significant progress being made by legislators and community groups."

"We are pleased to encourage public-private collaborations expanding access to naloxone," said Rain Henderson, CEO of the Clinton Health Matters Initiative. "We are hopeful this effort will facilitate a dialogue amongst students, educators, health professionals, and families about the risks of opioid overdose and ensure naloxone is available in schools that decide to take steps to address opioid overdose emergencies."

NASN President Beth Matthey noted that school nurses act as first responders in the school setting. "We educate our students, families, and school staff about prescription drug and substance abuse, and help families seek appropriate treatment and recovery options," Matthey said. "Having access to naloxone can save lives and is often the first step toward recovery. We are taking a proactive approach to address the possibility of a drug overdose in school."

Both programs build on Adapt Pharma's recently announced initiative to facilitate affordable access to NARCAN Nasal Spray. Earlier this month, Adapt Pharma, in partnership with the National Association of Counties, National Governors Association, National League of Cities and United States Conference of Mayors, announced it will offer NARCAN Nasal Spray at a discounted Public Interest Price through the U.S. Communities Purchasing Alliance and Premier, Inc. to over 62,000 state and local government agencies. Click [here](#) for further details.

### **NARCAN NASAL SPRAY INDICATION AND IMPORTANT SAFETY INFORMATION**

#### **INDICATIONS**

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate

administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

### **IMPORTANT SAFETY INFORMATION**

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

**Risk of Recurrent Respiratory and CNS Depression:** Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

**Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists:** Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

**Precipitation of Severe Opioid Withdrawal:** Use in patients who are opioid dependent may precipitate opioid withdrawal and acute withdrawal syndrome. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.

**Risk of Cardiovascular (CV) Effects:** Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

**The following adverse reactions were observed in a NARCAN Nasal Spray clinical study:** increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product.

Full prescribing information for NARCAN Nasal Spray, including important safety information, is also available at [www.NarcanNasalSpray.com](http://www.NarcanNasalSpray.com).

**To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

---

### **ABOUT ADAPT PHARMA**

Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma's company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit [www.adaptpharma.com](http://www.adaptpharma.com).